Business
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums\nPR Newswire\nSAN DIEGO, April 10, 2019\n\n\n\nSAN DIEGO, April 10, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced that its investment company AXIM® Biotechnologies (\"AXIM® Biotech\" or \"AXIM\") (OTCQB: AXIM), a world leader in cannabinoid research and development, has entered into a Services Agreement with contract research organization (\"CRO\") QPS Netherlands BV, a global leader in contract research, to begin separate bio comparison studies with its two leading drug candidates, MedChew® with Dronabinol and CanChew® Rx. Both products are chewing gums containing synthetic tetrahydrocannabinol (THC) and cannabidiol (CBD) respectively, and utilize the company's patented chewing gum delivery mechanism. \n\"We look forward to continuing our support for AXIM as they conduct these studies and remain optimistic about the company's positive future results,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"It is very important for us to be able to prove the efficacy and safety of our products and it is great to see that two of AXIM's developed products will be tested in these upcoming studies.\"\nThe CRO will conduct two open label single dose studies (varying chew duration and concentration) followed by a double-blind, randomized, multiple dose study to test the bioavailability of Dronabinol in MedChew®. MedChew® formulated with Dronabinol is intended for treatment of chemotherapy-induced nausea and vomiting in cancer and AIDS patients. AXIM® intends to register the product on the basis of a 505(b)(2) application.\nAn open-label, randomized, thre...